Aripiprazole Diminishes Cannabis Use in Schizophrenia

Total Page:16

File Type:pdf, Size:1020Kb

Aripiprazole Diminishes Cannabis Use in Schizophrenia LETTERS sant medications are preferred to could not resume her work and 6. Lenze EJ, Pollock BG, Shear MK, et al: benzodiazepines as a first-line of preferred to stay home to avoid sit- Treatment considerations for anxiety in the elderly. CNS Spectr 2003; 8(S3):6–13 treatment for anxiety disorders in uations that might provoke her the elderly.6 Psychotherapy, par- anxiety. She was prescribed sertra- ticularly cognitive behavior ther- line and was maintained on 150 apy, is often effective in these disor- mg/day. She reported lower anxi- Aripiprazole Diminishes 6 ders as well. ety level, became comfortable in Cannabis Use in We reviewed symptoms of three public, and decided to look for a cases in which onset of anxiety part-time job. Schizophrenia symptoms developed after age 60 The third case was a 75-year-old as a result of having a medical pro- male. He was a retired photogra- cedure. They were highly function- pher and developed minor neuro- To the Editor: Aripiprazole is the ing individuals and anxiety symp- logical deficits. Computed tomogra- first partial agonist dopaminergic toms led to impairment of their phy scan (CT) of the head was D2 with clear antipsychotic effect. social and occupational life. They conducted. After the image study, Many schizophrenic patients will were all successfully treated with he started to have periods of in- develop comorbid substance abuse. selective serotonin reuptake inhibi- tense fear and excessive worry cued Cannabis consumption may worsen tor medications without any side ef- by his presence in places from psychotic symptoms of schizo- fects and achieved the overall level which escape might be difficult. He phrenic patients.1 We describe the of functioning. isolated himself at home, stopped case of a schizophrenic patient The first case was a 61-year-old going to church services and the se- whose use of cannabis and related male who worked in graphic art. nior citizen center, and suffered de- problems disappeared after treat- He developed severe neck pains pression. He showed significant ment with aripiprazole. and a magnetic resonance imaging symptom response on paroxetine, Mr. A, a 33-year-old Caucasian scan (MRI) of cervical spines was 40 mg/day. patient with schizophrenia, has recommended. After having the Nahla A. Mahgoub, M.D. since his mid-20s been treated with MRI, he developed recurrent unex- Psychiatry, Weill Medical Col- olanzapine, 20 mg/day, and escital- pected panic attacks and anxiety lege of Cornell University, opram, 10 mg/day. He did reason- about being in a closed place. Com- New York ably well with this regimen but was muting to work caused marked dis- Jahandar Saifollahi, M.D. apragmatic. He frequently used tress and he subsequently avoided Melinda Lantz, M.D. cannabis every day (urine screen traveling in a bus, train, or car, and Geriatric Psychiatry, Beth Israel for tetrahydrocannabinol [THC] his daily activities were restricted. Medical Center, New York was positive). He was moderately He initially refused to consider any obese (BMI: 28) but had no other medications that might limit his medical problems. He lived in a creativity. He agreed to a trial of References community house, in which nurses sertraline, 50 mg/day, which was 1. Sadock BJ, Sadock VA: Geriatric psychi- ensured that he was compliant with increased gradually to 100 mg. He atry, in Kaplan and Sadock’s Synopsis treatment. His Brief Psychiatric Rat- noted significant improvement in of Psychiatry: Behavioral Sciences/ ing Scale (BPRS) score was 52. Be- intensity and frequency of his panic Clinical Psychiatry, 9th ed. Philadelphia, fore his mid-20s, the patient was Lippincott, Williams & Wilkins, 2002, pp attacks and regained the ability to 1318–1337 treated successively for different use the public transportation with- 2. Flint AJ: Management of anxiety in late classic antipsychotic conditions (i.e., out any fear. life. J Geriatr Psychiatr Neurol 1998; haloperidol, bromperidol, and pi- The second case involved a 61- 11:194–200 mozide) and he reported increased year-old female who was a medical 3. Rangaraj J, Pelissolo A: Anxiety disor- cannabis abuse concomitant with ders in the elderly: clinical and thera- technician. peutic aspects. Psychol Neuropsychiatr these regimens. She suffered gastrointestinal re- Vieil 2006; 4:179–187 Aripiprazole, 15 mg/day, was flux disease and underwent diag- 4. Flint AJ, Gagnon N: Diagnosis and man- added to his treatment regimen. Af- nostic upper endoscopy. Since then, agement of panic disorder in older pa- ter 1 week, the olanzapine dose was she had been feeling anxious, and tients. Drugs Aging 2003; 20:881–891 decreased to 10 mg. One week later, 5. Flint AJ: Epidemiology and comorbidity had poor concentration, frequent of anxiety disorders in later life: implica- olanzapine was discontinued. After unpredicted panic attacks, and tions for treatment. Clin Neurosci 1997; 5 weeks, escitalopram treatment anxiety about being in a crowd. She 4:31–36 was discontinued because the pa- J Neuropsychiatry Clin Neurosci 20:1, Winter 2008 117 LETTERS tient was euthymic. Three months patients may actually contribute to zole for alcohol dependence treatment. later, the patient signaled he felt greater substance use in an effort to Drugs Future 2003; 28:1227–1235 8,9 7. Warsi M, et al: Aripiprazole reduces al- very good and did not need canna- self-medicate the side effects. cohol use. Can J Psychiatry 2005; 50:244 bis anymore. After 12 months of Finally, there could be at least 8. McEvoy JP, et al: Haloperidol increases treatment with aripiprazole the pa- two explanations for the weight smoking in patients with schizophrenia. tient had not relapsed and did not loss. The reduction of cannabis use Psychopharmacology (Berl) 1995; use cannabis at all (urine screen did may have contributed to a reduc- 119:124–126 10 9. Siris SG: Pharmacological treatment of not reveal any THC). Moreover, his tion in eating, and the switch in substance-abusing schizophrenic pa- BMI was 24 and BPRS score de- the antipsychotic to aripiprazole tients. Schizophr Bull 1990; 16:111–122 creased to 40. may have been instrumental in 10. Kirkham TC: Endocannabinoids in the This case report highlights differ- such a significant weight reduction, regulation of appetite and body weight. ent proposals about mechanism of since aripiprazole is weight neutral Behav Pharmacol 2005; 16:297–313 action and side effects. and olanzapine is known to facili- First, the concurrence of the dimi- tate weight gain in patients. nution of cannabis consumption To our knowledge, this is the first Clinical Correlates of with the patient’s treatment with reported case of aripirpazole’s effect Personality Changes aripiprazole suggests that aripipra- on cannabis use. More research is zole contributed to the occurrence needed to establish the benefits of Associated With Traumatic of this diminution. Different mecha- aripiprazole in regard to cannabis. Brain Injury nisms may have played a part, such Some dual diagnosis patients may as aripirazole’s partial agonism at benefit from aripiprazole, which 2 dopamine D2 receptors. A similar may reduce craving for and use of To the Editor: Traumatic brain injury observation was made with cocaine cannabis. (TBI) is frequently complicated by dependence.3 Dopamine stimula- Martin Desseilles, M.D. alterations in temperament and tion in the nucleus accumbens has Department of Psychiatry, Uni- character that have adverse conse- been suggested to cause addictive versity of Lie`ge, Belgium quences for day-to-day living, man- behavior and aripiprazole’s partial Fernand Mathot, Pharm.D. ifesting as poor decision-making, dopamine agonist effect in this area Michel Desseilles, M.D. interpersonal problems, communi- may reduce this behavior.4 In addi- Psychiatric Hospital Centre cation problems, and often overall tion, aripiprazole has a number of “Le Petit-Bourgogne,” Lie`ge, poor quality of life.1 Max et al.2 serotonergic actions that are not re- Belgium have reported extensively on the lated to dopamine potentially mod- correlates and predictors of person- 5,6 ality changes after traumatic brain ulating the response to THC. References Other mechanisms may be involved injury in children, but there is scant and Mr. A’s rapid cessation of can- 1. Ujike H, Morita Y: New perspectives in mention in the literature on adults. the studies on endocannabinoid and In this report, we describe the re- nabis use after starting aripiprazole cannabis: cannabinoid receptors and suggests the need to verify these schizophrenia. J Pharmacol Sci 2004; sults of a preliminary study of the mechanisms systematically and to 96:376–381 clinical correlates of personality plan controlled trials. 2. Travis MJ, Burns T, Dursun S, et al: Ari- change following traumatic brain Second, several factors have to be piprazole in schizophrenia: consensus injury in adults. guidelines. Int J Clin Pract 2005; 59:485– considered when regarding why 495 there may be a concomitant in- 3. Beresford TP, et al: Aripiprazole in Analysis crease in substance abuse with the schizophrenia with cocaine dependence: Data are from a retrospective chart older antipsychotics. It was sug- a pilot study. J Clin Psychopharmacol review of 54 subjects with closed gested that a strong antagonist ef- 2005; 25:363–366 head injury enrolled in an outpa- 4. Pilla M, et al: Selective inhibition of co- fect at the dopamine D2 receptors in caine-seeking behaviour by a partial do- tient neuropsychiatry brain injury the nucleus accumbens was in- pamine D3 receptor agonist. Nature clinic. Patients with depressed skull volved in concomitant increase in 1999; 400:371–375 fractures were excluded. substance abuse with old antipsy- 5. Kenna GA, McGeary JE, Swift RM: Every patient was evaluated and chotics.7 Moreover, unrelated to do- Pharmacotherapy, pharmacogenomics, followed by a clinic psychiatrist. and the future of alcohol dependence paminergic mechanisms, the use of treatment, part 2.
Recommended publications
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Revision of Precautions Asenapine Maleate, Aripiprazole, Olanzapine
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Asenapine maleate, aripiprazole, olanzapine, quetiapine fumarate, clocapramine hydrochloride hydrate, chlorpromazine hydrochloride, chlorpromazine hydrochloride/promethazine hydrochloride/phenobarbital, chlorpromazine phenolphthalinate, spiperone, zotepine, timiperone, haloperidol, paliperidone, pipamperone hydrochloride, fluphenazine decanoate, fluphenazine maleate, brexpiprazole, prochlorperazine maleate, prochlorperazine mesilate, Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. propericiazine, bromperidol, perphenazine, perphenazine hydrochloride, perphenazine fendizoate, perphenazine maleate, perospirone hydrochloride hydrate, mosapramine hydrochloride, risperidone (oral drug), levomepromazine hydrochloride, levomepromazine maleate March 27, 2018 Non-proprietary name Asenapine maleate,
    [Show full text]
  • Antipsychotics and the Risk of Sudden Cardiac Death
    ORIGINAL INVESTIGATION Antipsychotics and the Risk of Sudden Cardiac Death Sabine M. J. M. Straus, MD; Gyse`le S. Bleumink, MD; Jeanne P. Dieleman, PhD; Johan van der Lei, MD, PhD; Geert W. ‘t Jong, PhD; J. Herre Kingma, MD, PhD; Miriam C. J. M. Sturkenboom, PhD; Bruno H. C. Stricker, PhD Background: Antipsychotics have been associated with Results: The study population comprised 554 cases of prolongation of the corrected QT interval and sudden car- sudden cardiac death. Current use of antipsychotics was diac death. Only a few epidemiological studies have in- associated with a 3-fold increase in risk of sudden car- vestigated this association. We performed a case- diac death. The risk of sudden cardiac death was high- control study to investigate the association between use est among those using butyrophenone antipsychotics, of antipsychotics and sudden cardiac death in a well- those with a defined daily dose equivalent of more than defined community-dwelling population. 0.5 and short-term (Յ90 days) users. The association with current antipsychotic use was higher for witnessed cases Methods: We performed a population-based case-control (n=334) than for unwitnessed cases. study in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with com- Conclusions: Current use of antipsychotics in a gen- plete medical records from 150 general practitioners. All eral population is associated with an increased risk of sud- instances of death between January 1, 1995, and April 1, den cardiac death, even at a low dose and for indica- 2001, were reviewed. Sudden cardiac death was classified tions other than schizophrenia.
    [Show full text]
  • Centre for Reviews and Dissemination
    Bromperidol decanoate (depot) for schizophrenia Purgato Marianna, Adams Clive E Authors' objectives Background: Antipsychotic drugs are the mainstay treatment for schizophrenia. Long-acting depot injections of drugs such as bromperidol decanoate are extensively used as a means of long-term maintenance treatment.Objectives: To assess the effects of depot bromperidol versus placebo, oral antipsychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes.Search methods: For this 2012 update we searched the Cochrane Schizophrenia Group's Register (February 2012).Selection criteria: We sought all randomised trials focusing on people with schizophrenia where depot bromperidol, oral antipsychotics or other depot preparations. Primary outcomes were clinically significant change in global function, service utilisation outcomes (hospital admission, days in hospital), relapse.Data collection and analysis: For the 2011 update MP independently extracted data, CEA carried out the reliability check. We calculated fixed-effect risk ratios (RR) and 95% confidence intervals (CI) for dichotomous data, and calculated weighted or standardised means for continuous data. Where possible, we calculated the number needed to treat statistic (NNT). Analysis was by intention-to-treat.For the 2012 update, data collection and analysis was not carried out as no new studies were found.Main results: The 2012 search found no new studies, we have therefore included no new trials in this 2012 update. The number of included trials remain 4 RCTs, total n = 117. A single, small study of six months' duration compared bromperidol decanoate with placebo injection. Similar numbers left the study before completion (n = 20, 1 RCT, RR 0.4 CI 0.1 to 1.6) and there were no clear differences between bromperidol decanoate and placebo for a list of adverse effects (n = 20, 1 RCT, RR akathisia 2.0 CI 0.21 to 18.69, RR increased weight 3.0 CI 0.14 to 65.9, RR tremor 0.33 CI 0.04 to 2.69).
    [Show full text]
  • Paliperidone Palmitate in Non-Acute Patients with Schizophrenia Previously Unsuccessfully
    JOP0010.1177/0269881115586284Journal of PsychopharmacologySchreiner et al. 586284research-article2015 Original Paper Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy Journal of Psychopharmacology 1 –13 or frequently used conventional depot © The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav antipsychotics DOI: 10.1177/0269881115586284 jop.sagepub.com A Schreiner1, P Bergmans2, P Cherubin3, S Keim4, P-M Llorca5, B Cosar6, A Petralia7, G Corrivetti8 and L Hargarter1 Abstract PALMFlexS, a prospective multicentre, open-label, 6-month, phase IIIb interventional study, explored tolerability, safety and treatment response in adults (n = 231) with non-acute but symptomatic schizophrenia switching to flexibly dosed paliperidone palmitate (PP) after unsuccessful treatment with risperidone long-acting injectable therapy (RLAT) or conventional depot antipsychotics (APs). Treatment response was measured by change in Positive and Negative Syndrome Scale (PANSS) total score from baseline (BL) to last-observation-carried-forward (LOCF) endpoint (EP). Safety and tolerability assessments included Extrapyramidal Symptom Rating Scale (ESRS) total score and treatment-emergent adverse events. Significant reductions in mean PANSS total score were observed for all groups (–7.5 to –10.6; p ⩽ 0.01 [BL to LOCF EP]). After switching to PP, more than 50% of all patients achieved ⩾20% and one-third of RLAT-treated patients even achieved ⩾50% improvement in PANSS total score. Across groups, there were significant improvements (p < 0.05) in symptom severity as measured by Clinical Global Impression-Severity (CGI-S; trend for improvement with RLAT; p = 0.0568), subjective well-being, medication satisfaction, and patient functioning with PP.
    [Show full text]
  • Current Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 3385 Cur rent Topics in Medicinal Chemistry, 2016, 16, 3385-3403 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-5294 Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Impact Factor: 2.9 The international Present and Future journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Peng Li*, Gretchen L. Snyder and Kimberly E. Vanover Intra-Cellular Therapies Inc, 430 East 29th Street, Suite 900, New York, NY 10016, USA Abstract: Schizophrenia is a chronic and debilitating neuropsychiatric disorder affecting approxi- mately 1% of the world’s population. This disease is associated with considerable morbidity placing a major financial burden on society. Antipsychotics have been the mainstay of the pharmacological treatment of schizophrenia for decades. The traditional typical and atypical antipsychotics demon- strate clinical efficacy in treating positive symptoms, such as hallucinations and delusions, while are A R T I C L E H I S T O R Y largely ineffective and may worsen negative symptoms, such as blunted affect and social withdrawal, as well as cognitive function. The inability to treat these latter symptoms may contribute to social Received: April 07, 2016 Revised: May 20, 2016 function impairment associated with schizophrenia. The dysfunction of multiple neurotransmitter Accepted: May 23, 2016 systems in schizophrenia suggests that drugs selectively targeting one neurotransmission pathway DOI: 10.2174/1568026616666160608 are unlikely to meet all the therapeutic needs of this heterogeneous disorder. Often, however, the un- 084834 intentional engagement of multiple pharmacological targets or even the excessive engagement of in- tended pharmacological targets can lead to undesired consequences and poor tolerability.
    [Show full text]
  • Withdrawal Versus Continuation of Long-Term Antipsychotic Drug Use for Behavioural and Psychological Symptoms in Older People with Dementia (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography Cochrane Database of Systematic Reviews Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia (Review) Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AIM, Vander Stichele R, Declercq T, Christiaens T Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AIM, Vander Stichele R, Declercq T, Christiaens T. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with de- mentia. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD007726. DOI: 10.1002/14651858.CD007726.pub3. www.cochranelibrary.com Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 Figure1. ..................................... 8 BACKGROUND .................................... 8 OBJECTIVES ..................................... 9 METHODS ...................................... 9 RESULTS....................................... 12 Figure2. ..................................... 13 Figure3. ....................................
    [Show full text]
  • Pharmacology Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200603 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology/Toxicology Review From: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 200603 Agency receipt date: 12/30/2009 Drug: Lurasidone hydrochloride Applicant: Sunovion Pharmaceuticals (Originally submitted by Dainippon Sumimoto Pharma America, Inc.) Indication: schizophrenia Reviewing Division: Division of Psychiatry Products Background: The pharm/tox reviewer and team leader concluded that the nonclinical data support approval of lurasidone for the indication listed above. Reproductive and Developmental Toxicity: Reproductive and developmental toxicity studies in rats and rabbits revealed no evidence of teratogenicity or embryofetal toxicity. The high doses in the rat and rabbit embryofetal toxicity studies were 3 and 12 times, respectively, the maximum recommended human dose (80 mg) based on a body surface area comparison. Carcinogenicity: Lurasidone was tested in 2 year rat and mouse carcinogenicity studies. These studies were reviewed by the division and the executive carcinogenicity assessment committee. The committee concluded that the studies were adequate and that there was a drug-related increase in mammary carcinomas in female rats at doses of 12 mg/kg and higher and a drug-related increase in mammary carcinomas and adenoacanthomas and pituitary pars distalis adenomas in female mice. The applicant also provided data from various studies showing that lurasidone significantly increases prolactin in several different species including rats and mice. Conclusions: I agree with the division pharm/tox conclusion that this application can be approved from a pharm/tox perspective. The division recommends that lurasidone be labeled with pregnancy category B.
    [Show full text]
  • Improvement in Antipsychotic-Induced Hyperprolactinemia with the Addition of Aripiprazole in Schizophrenic Patients
    Original Contribution CNPT 1 (2010) 1-5 Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients Kazuo Mihara, M.D., Ph.D., Goyo Nagai, M.D., Ph.D., Akifumi Nakamura, M.D., Ph.D., Yasuhide Fukuji, M.D., Takeshi Suzuki, M.S., Pharm., Tsuyoshi Kondo, M.D., Ph.D . Department of Neuropsychiatry, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan ABSTRACT Purpose: Hyperprolactinemia, a common adverse effect of antipsychotics, frequently impacts patients’ quality of life. Aripiprazole is a potent dopamine D2 receptor partial agonist and rarely increases the serum prolactin concentration. The authors investigated the effect of aripiprazole coadministration on antipsychotic-induced hyperprolactinemia and associated symptoms in patients with schizophrenia. Method: The subjects were 9 patients (8 females, 1 male) with hyperprolactinemia induced by risperidone, olanzapine, haloperidol, zotepine, bromperidol, levomepromazine, and quetiapine; 6 of the females had oligomenorrhea and 2 amenorrhea, and the male had erectile dysfunction. All of the patients received concomitant aripiprazole for more than 8 weeks at a mean dose (range) of 7.7 (3-18) mg/day. The doses of all other medications, including the hyperprolactinemia-inducing antipsychotics, remained fixed throughout the study period. Results: The mean serum concentration (range) of prolactin during aripiprazole coadministration (29.9 (9.8-53) ng/ml) was significantly (p=0.008) lower than that before aripiprazole coadministration (81.1 (27-153) ng/ml). The associated symptoms were improved in 4 females (regularized or regained menstruation) and the male (normalized erectile function), while no changes were observed in the other clinical symptoms of schizophrenia. Discussion: The results of the present study suggest that even small doses of coadministered aripiprazole effectively limit excessive prolactin response to antipsychotics without interfering with the benefits of existing prescriptions.
    [Show full text]
  • Antipsychotics for Treatment of Delirium in Hospitalised Non-ICU Patients
    This is a repository copy of Antipsychotics for treatment of delirium in hospitalised non-ICU patients. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/132847/ Version: Published Version Article: Burry, Lisa, Mehta, S.R., Perreault, M.M et al. (6 more authors) (2018) Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews. CD005594. ISSN 1469-493X https://doi.org/10.1002/14651858.CD005594.pub3 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Database of Systematic Reviews Antipsychotics for treatment of delirium in hospitalised non- ICU patients (Review) Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database of Systematic Reviews 2018, Issue 6.
    [Show full text]
  • Australian Public Assessment for Paliperidone Palmitate
    Australian Public Assessment Report for Paliperidone palmitate Proprietary Product Names: Invega Trinza and Trevicta Sponsor: Janssen-Cilag Pty Ltd October 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au> . About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. · An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]